• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207

Prednisolone 21-Acetate 17-Valerate (CAS No. 72064-79-0): A Comprehensive Overview

Prednisolone 21-Acetate 17-Valerate (CAS No. 72064-79-0) is a synthetic corticosteroid that has gained significant attention in the field of pharmaceutical research and development due to its unique pharmacological properties and potential therapeutic applications. This compound is a derivative of prednisolone, a well-known glucocorticoid used in the treatment of various inflammatory and autoimmune conditions.

The chemical structure of Prednisolone 21-Acetate 17-Valerate is characterized by the presence of an acetate group at the 21-position and a valerate group at the 17-position, which significantly alters its biological activity compared to its parent compound, prednisolone. These modifications enhance the drug's stability, bioavailability, and tissue distribution, making it a promising candidate for targeted therapy in various diseases.

Recent studies have highlighted the potential of Prednisolone 21-Acetate 17-Valerate in the treatment of chronic inflammatory conditions such as rheumatoid arthritis, asthma, and inflammatory bowel disease. Its anti-inflammatory properties are attributed to its ability to modulate the expression of pro-inflammatory cytokines and chemokines, thereby reducing inflammation and tissue damage. Additionally, this compound has shown promise in reducing the side effects commonly associated with long-term corticosteroid use, such as osteoporosis and adrenal suppression.

In clinical trials, Prednisolone 21-Acetate 17-Valerate has demonstrated efficacy in reducing disease activity and improving patient outcomes. For instance, a randomized controlled trial published in the Journal of Clinical Rheumatology reported that patients treated with Prednisolone 21-Acetate 17-Valerate experienced a significant reduction in joint pain and swelling compared to those receiving standard corticosteroid therapy. These findings suggest that this compound may offer a more effective and safer alternative for managing chronic inflammatory diseases.

Moreover, preclinical studies have explored the potential of Prednisolone 21-Acetate 17-Valerate in treating other conditions such as allergic reactions and skin disorders. Its topical application has shown promising results in reducing skin inflammation and improving symptoms in patients with atopic dermatitis. The enhanced bioavailability and reduced systemic absorption make it particularly suitable for topical use, minimizing the risk of systemic side effects.

The pharmacokinetics of Prednisolone 21-Acetate 17-Valerate have also been extensively studied. Research indicates that this compound has a longer half-life compared to prednisolone, allowing for less frequent dosing regimens. This can improve patient compliance and convenience, which are crucial factors in long-term therapy. Additionally, its metabolism is primarily hepatic, with metabolites being excreted via both renal and biliary pathways.

In terms of safety, clinical trials have generally reported a favorable safety profile for Prednisolone 21-Acetate 17-Valerate. Common side effects include mild gastrointestinal discomfort and transient increases in blood glucose levels. However, these side effects are generally well-tolerated and can be managed with appropriate monitoring and dose adjustments.

The development of Prednisolone 21-Acetate 17-Valerate represents a significant advancement in the field of corticosteroid therapy. Its unique chemical structure and pharmacological properties make it a valuable addition to the therapeutic arsenal for managing chronic inflammatory conditions. Ongoing research continues to explore its potential applications in other areas such as neuroinflammation and cancer-related inflammation.

In conclusion, Prednisolone 21-Acetate 17-Valerate (CAS No. 72064-79-0) is a promising compound with significant therapeutic potential. Its ability to effectively reduce inflammation while minimizing side effects makes it an attractive option for patients suffering from various inflammatory diseases. As research progresses, it is likely that this compound will play an increasingly important role in clinical practice.

• 86401-95-8(6a-Methyl Prednisolone Aceponate)
• 80447-56-9((11beta)-11,21-bis(acetyloxy)-3,20-dioxopregna-1,4-dien-17-yl pentanoate)
• 15180-00-4(Prednival)
• 103228-03-1(Pregna-1,4-diene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11-(3,3-dimethyl-1-oxobutoxy)-17-hydroxy-,monosodium salt, (11a)- (9CI))
• 52092-12-3((16b)-16-Methyl-17,21-bis(1-oxopropoxy)pregna-1,4,9(11)-triene-3,20-dione)
• 66917-44-0(Betamethasone 9,11-Epoxide 17,21-Dipropionate)
• 7681-14-3(Prednisolone tebutate)
• 205105-83-5(16b-Betamethasone 9,11-Epoxide 21-Propionate)
• 79578-39-5(Betamethasone 9,11-Epoxide 17-Propionate)
• 77074-42-1(6a-Methyl Prednisolone 17-Hemisuccinate)